All Photos(1)



Propranolol hydrochloride

United States Pharmacopeia (USP) Reference Standard

(±)-1-Isopropylamino-3-(1-naphthyloxy)-2-propanol hydrochloride, DL-Propranolol hydrochloride, (±)-Propranolol hydrochloride
Empirical Formula (Hill Notation):
C16H21NO2 · HCl
CAS Number:
Molecular Weight:
MDL number:
PubChem Substance ID:


pharmaceutical primary standard




pharmaceutical (small molecule)



SMILES string




InChI key


Gene Information

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

USP issued SDS can be found here.
Sales restrictions may apply.


Exclamation mark

Signal Word


Hazard Statements

Precautionary Statements

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

13 - Non Combustible Solids



Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis

Certificate of Origin

Pawel Szychta et al.
Plastic and reconstructive surgery, 133(4), 852-862 (2013-12-20)
Infantile hemangioma is a vascular tumor and requires treatment in lesions manifested by potentially dangerous symptoms. Several publications have reported that involution of infantile hemangioma could be accelerated by propranolol but have used only invalidated subjective measures of assessment. The
Katherine B Püttgen
Pediatric clinics of North America, 61(2), 383-402 (2014-03-19)
Propranolol has replaced corticosteroids as preferred first-line therapy for the management of infantile hemangiomas (IH). The topical β-blocker timolol is now an alternative to oral propranolol and watchful waiting for smaller IH. Research in the last decade has provided evidence-based
Canan Akyüz et al.
Pediatric blood & cancer, 61(5), 931-932 (2013-11-23)
Lymphangiomas of the tongue are rare, and their treatment is problematic. A 10 year-old patient with tongue lymphangioma who was previously treated with surgery and propranolol with no response was treated with sirolimus in our department. We used sirolimus with
Dennis D Rasmussen et al.
Alcoholism, clinical and experimental research, 38(6), 1532-1539 (2014-06-04)
Evidence suggests that activation of the noradrenergic system may contribute to alcohol drinking in animals and humans. Our previous studies demonstrated that blocking α1 -adrenergic receptors with the antagonist, prazosin, decreased alcohol drinking in rats under various conditions. As noradrenergic
Alvaro Ábarzúa-Araya et al.
Journal of the American Academy of Dermatology, 70(6), 1045-1049 (2014-03-25)
Infantile hemangiomas have a dramatic response to propranolol, a nonselective beta-blocker. However, this treatment is not risk-free and many patients are excluded because of respiratory comorbidities. Atenolol is a cardioselective beta-blocker that may have fewer adverse events. We sought to

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service